| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
In the last three months, 11 analysts have published ratings on Ultragenyx Pharmaceutical (NASDAQ:RARE), offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 5 | 3 | 0 | 0 |
| Last 30D | 1 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 1 | 0 | 0 |
| 2M Ago | 1 | 2 | 2 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $81.36, with a high estimate of $127.00 and a low estimate of $47.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.98%.
In examining recent analyst actions, we gain insights into how financial experts perceive Ultragenyx Pharmaceutical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Dae Gon Ha | Stifel | Raises | Buy | $127.00 | $124.00 |
| Joel Beatty | Baird | Raises | Outperform | $72.00 | $68.00 |
| Whitney Ijem | Canaccord Genuity | Lowers | Buy | $109.00 | $111.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Overweight | $107.00 | - |
| Laura Chico | Wedbush | Lowers | Neutral | $47.00 | $48.00 |
| Yaron Werber | TD Cowen | Raises | Buy | $61.00 | $59.00 |
| Luca Issi | RBC Capital | Announces | Outperform | $77.00 | - |
| Laura Chico | Wedbush | Maintains | Neutral | $48.00 | - |
| Laura Chico | Wedbush | Maintains | Neutral | $48.00 | - |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Overweight | $107.00 | - |
| Anupam Rama | JP Morgan | Raises | Overweight | $92.00 | $88.00 |
For valuable insights into Ultragenyx Pharmaceutical's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Ultragenyx Pharmaceutical analyst ratings.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Ultragenyx Pharmaceutical showcased positive performance, achieving a revenue growth rate of 8.3% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Ultragenyx Pharmaceutical's net margin is impressive, surpassing industry averages. With a net margin of -156.83%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Ultragenyx Pharmaceutical's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -82.12%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Ultragenyx Pharmaceutical's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -12.2%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Ultragenyx Pharmaceutical's debt-to-equity ratio is below the industry average. With a ratio of 0.29, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: RARE
